Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
Ivar S JensenElizabeth WuPhilip L CyrMarc ClaussenThomas WinklerKhalid SalahuddinJayne PratsKenneth W MahaffeyCharles Michael GibsonPhilippe Gabriel StegGregg W StoneDeepak L BhattPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
Use of cangrelor in patients with two or more angiographic HRFs may improve outcomes and lower hospital budgets, mainly from avoiding surgery delays necessitated by oral P2Y12 inhibitor pretreatment.
Keyphrases
- percutaneous coronary intervention
- end stage renal disease
- coronary artery bypass
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- minimally invasive
- acute coronary syndrome
- acute myocardial infarction
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute care
- emergency department
- adverse drug
- coronary artery bypass grafting
- type diabetes
- antiplatelet therapy
- metabolic syndrome
- skeletal muscle
- adipose tissue
- insulin resistance
- weight loss